Skip to main
OCX
OCX logo

OncoCyte (OCX) Earnings Dates & Reports

OncoCyte (OCX) Most Recent Earnings

Report DateNov 10, 2022
Period EndingQ3 2022
Est. EPS-$2.20
Actual EPS-$1.60
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

OncoCyte (OCX) Earnings per Share (EPS) History

Signup for full access
Browse free

OncoCyte (OCX) Latest Earnings

The value each OCX share was expected to gain vs. the value each share gained.

OncoCyte (OCX) reported its most recent earnings on Nov 10, 2022 for Q3 2022, posting earnings per share (EPS) of -$1.60. This exceeded analysts' expectations of -$2.20 by 27.27%, marking a Beat.

For comparison, OncoCyte reported EPS of -$2 in the same quarter last year.

The company is expected to announce its next earnings report on 04/03/2023, with analysts projecting an EPS of -$1.80.

OncoCyte (OCX) Earnings History

Earnings
Est. EPSActual EPSSurprise
Q4 2022Apr 3, 2023
-$1.80Next earnings call Apr. 3, 2023
Q3 2022Nov 10, 2022
-$2.20-$1.60-27.27%
DeckReportListen
Q2 2022Aug 10, 2022
-$2.20-$2.00-9.09%
Q1 2022May 11, 2022
-$2.40-$2.20-8.33%
Q4 2021Mar 10, 2022
-$2.60-$1.20-53.85%
View all

OncoCyte (OCX) Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the OncoCyte’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange
Nov 10, 2022
Aug 10, 2022
May 11, 2022
Mar 10, 2022

OncoCyte (OCX) Earnings FAQs

OncoCyte (OCX) last reported earnings on Nov 10, 2022 for Q3 2022, posting an EPS of -$1.60, which Beat the estimate of -$2.20 by 27.27%.

For Q3 2022, OncoCyte (OCX) reported an EPS of -$1.60, exceeding analysts' estimate of -$2.20 by 27.27%.

For Q3 2022, OncoCyte (OCX) Beat expectations with an actual EPS of -$1.60 vs. an estimated EPS of -$2.20.

Following the last earnings report on Nov 10, 2022, OncoCyte (OCX)'s stock price moved — from — to —.

The next OncoCyte (OCX) earnings call is scheduled for Apr. 3, 2023, where executives will discuss financial results and outlook.

OncoCyte (OCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.